Madeléne Sandqvist
University of Gothenburg
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Madeléne Sandqvist.
The FASEB Journal | 2003
Per-Anders Jansson; Fredrik Pellmé; Ann Hammarstedt; Madeléne Sandqvist; Hilde Kristin Brekke; Kenneth Caidahl; Margareta Forsberg; Reinhard Volkmann; Eugénia Carvalho; Tohru Funahashi; Yuji Matsuzawa; Olle Wiklund; Xiaolin Yang; Marja-Riitta Taskinen; Ulf Smith
The epidemic increase in type 2 diabetes can be prevented only if markers of risk can be identified and used for early intervention. We examined the clinical phenotype of individuals characterized by normal or low IRS‐1 protein expression in fat cells as well as the potential molecular mechanisms related to the adipose tissue. Twenty‐five non‐obese individuals with low or normal IRS‐1 expression in subcutaneous abdominal fat cells were extensively characterized and the results compared with 71 carefully matched subjects with or without a known genetic predisposition for type 2 diabetes. In contrast to the commonlyused risk marker, knownheredity for diabetes, low cellular IRS‐1 identified individuals who were markedly insulin resistant, had high proinsulin and insulin levels, and exhibited evidence of early atherosclerosis measured as increased intima media thickness in the carotid artery bulb. Circulating levels of adiponectin were also significantly reduced. Gene analyses of fat cells in a parallel study showed attenuated expression of several genes related to fat cell differentiation (adiponectin, aP2, PPARγ, and lipoprotein lipase) in the group of individuals characterized by a low IRS‐1 expression and insulin resistance. A low IRS‐1 expression in fat cells is a marker of insulin resistance and risk for type 2 diabetes and is associated with evidence of early vascular complications. Impaired adipocyte differentiation, including low gene expression and circulating levels of adiponectin, can provide a link between the cellular marker and the in vivo phenotype.—Jansson, P.‐A., Pellmé, F., Hammarstedt, A., Sandqvist, M., Brekke, H., Caidahl, K., Forsberg, M., Volkmann, R., Carvalho, E., Funahashi, T., Matsuzawa, Y., Wiklund, O., Yang, X., Taskinen, M.‐R., Smith, U. A novel cellular marker of insulin resistance and early atherosclerosis in humans is related to impaired fat cell differentiation and low adiponectin. FASEB J. 17, 1434–1440 (2003)
The Journal of Clinical Endocrinology and Metabolism | 2011
Madeléne Sandqvist; Lena Strindberg; Martin Schmelz; Peter Lönnroth; Per-Anders Jansson
CONTEXT An impaired transfer of insulin from the circulation to the interstitial fluid has been suggested to contribute to insulin resistance. OBJECTIVE The objective of the study was to address whether the delivery of insulin from the circulation to adipose tissue and skeletal muscle is impaired in obese women with postprandial hyperglycemia compared with lean healthy controls. DESIGN, SETTING, AND PARTICIPANTS Seven obese nondiabetic women with postprandial hyperglycemia and nine lean healthy women were recruited. The interstitial insulin concentration in adipose tissue and muscle tissue was measured by the microdialysis technique during an oral glucose tolerance test (75 g). In parallel, arterial insulin levels were measured. We used ¹³³Xe clearance and plethysmography to monitor blood flow. Subcutaneous needle biopsies were taken to obtain fat cell size. RESULTS After oral glucose ingestion, mean arterial insulin levels were higher in obese women than in the lean group. However, interstitial insulin levels in sc adipose tissue and forearm muscle were similar in both groups. Accordingly, the proportion of circulating insulin being transported across the vascular endothelium to the interstitial fluid in adipose tissue and in muscle tissue was significantly lower in the obese compared with the lean group. CONCLUSIONS Obese subjects with postprandial hyperglycemia need higher circulating insulin levels than lean controls to attain similar interstitial insulin levels in adipose tissue and skeletal muscle, indicating an impaired transfer of insulin across the endothelium.
Diabetes-metabolism Research and Reviews | 2005
Else Hellebö Johanson; Per-Anders Jansson; Birgit Gustafson; Madeléne Sandqvist; M.-R. Taskinen; Ulf Smith; Mette Axelsen
To study the acute effect of nateglinide, an insulinotropic agent, on the postprandial triglyceride and lipoprotein responses in subjects at risk for type 2 diabetes.
European Journal of Clinical Investigation | 2006
Madeléne Sandqvist; Eh Johanson; Bo Ahrén; M Axelsen; Martin Schmelz; Ulf Smith; Per-Anders Jansson
Background An endothelial barrier for the insulin transport from the circulation to the target tissues of insulin has previously been suggested to contribute to insulin resistance. The interstitial insulin concentration (I‐insulin) and insulin kinetics following a mixed meal have, however, previously not been characterized in human adipose tissue.
Molecular and Cellular Biochemistry | 2011
Emelie Wallerstedt; Madeléne Sandqvist; Ulf Smith; Christian X. Andersson
The liver is an important target for interleukin-6 (IL-6) action leading to an increased inflammatory response with impaired insulin signaling and action. The aims of this study are to address if insulin is anti-inflammatory and attenuates IL-6-induced inflammation in the human hepatoma cell line HepG2 and if this involves signal transducer and activator of transcription 3 (STAT3) signal transduction. It was found that insulin significantly reduced IL-6-induced gene transcription of serum amyloid 1 (SAA1), serum amyloid 2 (SAA2), haptoglobin, orosomucoid, and plasmin activator inhibitor-1 (PAI-1). However, the authors did not find any evidence that insulin inhibited IL-6 signal transduction, i.e., no effect of insulin was detected on STAT3 phosphorylation or its translocation to cell nucleus. The potential role of PKCδ was also analyzed but no evidence of its involvement was found. Taken together, these results suggest that the anti-inflammatory effect of insulin on IL-6 action is exerted at the level of the transcriptional activation of the genes. Further analysis revealed that insulin regulates nuclear localization of FOXO1, which is an important co-activator for STAT3 mediated transcription. Insulin induced nuclear exit and Thr24 phosphorylation of FOXO1, thus, inhibiting STAT3-mediated transcription.
Hormone and Metabolic Research | 2013
Madeléne Sandqvist; Lena Strindberg; Peter Lönnroth; Per-Anders Jansson
Insulin-mediated microvascular recruitment is recognized as a potential mechanism contributing to insulin resistance. In this study, we compared a marker of microvascular function, the permeability surface area for glucose (PS(glu)), and forearm glucose uptake after an OGTT in obese women with impaired glucose metabolism and healthy lean nondiabetic women, with the aim to characterize whether decreased permeability surface area for glucose or decreased glucose uptake may contribute to postprandial hyperglycemia in the obese group. In addition, we evaluated whether the phosphodiesterase-5 (PDE-5) inhibitor tadalafil, in a randomized double blind placebo controlled design, might attenuate postprandial glucose levels in obese women. For these purposes, intramuscular microdialysis, blood sampling from arterial and venous blood of the forearm, and measurements of forearm blood flow were performed. The results showed an impaired permeability surface area for glucose (IAUC PS(glu) 31±13 vs. 124±31; p<0.05) in obese when compared with lean participants, but no differences in forearm glucose uptake appeared between the groups. Furthermore, a single dose of tadalafil 10 mg showed no improvement of the permeability surface area for glucose, glucose uptake, or circulating glucose levels in obese participants. In conclusion, the postprandial PS(glu) response was impaired in obese women showing postprandial hyperglycemia, indicating a compromised microcirculation. However, we were unable to demonstrate any acute effect on either vascular function or glucose uptake of the phosphodiesterase-5 (PDE-5) inhibitor tadalafil.
Diabetes Care | 2002
Bo Ahrén; Erik Simonsson; Hillevi Larsson; Mona Landin-Olsson; Hlin Torgeirsson; Per-Anders Jansson; Madeléne Sandqvist; Peter Båvenholm; Suad Efendic; Jan W. Eriksson; Sheila Dickinson; David Holmes
Obesity Research | 2004
Victoria Rotter Sopasakis; Madeléne Sandqvist; Birgit Gustafson; Ann Hammarstedt; Martin Schmelz; Xiaolin Yang; Per-Anders Jansson; Ulf Smith
The Journal of Clinical Endocrinology and Metabolism | 2007
Giuseppe Murdolo; Ann Hammarstedt; Madeléne Sandqvist; Martin Schmelz; Christian Herder; Ulf Smith; Per-Anders Jansson
Diabetes | 2001
Madeléne Sandqvist; Jan W. Eriksson; Per-Anders E. Jansson